"it seems like the story is morphing as we go along."
You're being kind.
Just to review:
On June 11th we heard that "The lead researchers at both the RBL and at the PHRI have informed the Company they plan to submit their findings, separately, upon completion of in vitro testing, for peer-review publication."
The 8/4 IPIX headline said...
"Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing".
...and
"Article to be submitted for peer-review publication in September, with pre-print made available"
Nothing of substance regarding the PHRI has been heard since 5/26 when IPIX reported "receiving data from a leading Public Health Research Institute (PHRI) showing Brilacidin inhibits SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human cell line."
Your "morphing" concept...
"the peer review doc will be once in vivo testing is done... which seems dependent upon a federal grant we did in collaboration with the rbl (most likely gmu)"
....is less morphing than it is totally changing the expectation that was provided.
In vivo testing was brought up in the same June 11th PR that announced publication upon completion of in vitro testing. And it wasn't just dependent upon a federal grant we did in collaboration with the rbl as you said, but also that it was in conjunction with research on something IN ADDITION TO B-Covid:
"The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing."
That's a two stage morph and any paper reporting in vivo testing of B in the treatment of those other diseases should be in addition to, not instead of, the preprints and peer reviews planned after in vitro testing of B-Covid. WAITING for in vivo test results in the treatment multiple viruses violates the spirit and the language of the June 11th PR.
Calling it "morphing" is way too kind and I sure hope that's not some new, unannounced plan.
The Company confirmed the original RBL plan on 9/15:
"The Company has been informed by the RBL that it is nearing completion of its in vitro testing of Brilacidin against SARS-CoV-2 and will be submitting findings for peer-review publication. The publication will be solely focused on Brilacidin, with a pre-print made available."
I understand your concern, but except that things are moving more slowly than expected when it comes to a preprint, the Company has not SAID anything to suggest that the original plan has changed. That said, they haven't confirmed the status of that plan lately.
---------------------------------------------------
WAKEFIELD, MA – June 11, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.
The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing. Longer-term objectives include potentially performing additional research to develop Brilacidin as a broad-spectrum antiviral, with possible application beyond coronaviruses, e.g., treating other viruses, such as encephalitic alphaviruses and filoviruses.
The ongoing Brilacidin anti-SARS-CoV-2 research being conducted at the RBL is separate from the ongoing research being performed at a Public Health Research Institute (PHRI). The lead researchers at both the RBL and at the PHRI have informed the Company they plan to submit their findings, separately, upon completion of in vitro testing, for peer-review publication.
---------------------------------------------------
News 
Market Data 
Discover 
